Published in JAMA on April 04, 2007
Women's Health Initiative (WHI) | NCT00000611
Data Analyses for Ancillary WISE Femhrt Hormone Replacement Study | NCT00600106
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12
Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One (2014) 6.01
Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet (2009) 5.22
Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. Ann Intern Med (2010) 4.27
The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause (2012) 4.04
Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst (2009) 3.89
Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA (2011) 3.85
Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol (2008) 3.63
Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol (2009) 3.33
Evidence-based common sense? Can Fam Physician (2008) 2.67
Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. J Gen Intern Med (2008) 2.64
Vascular actions of estrogens: functional implications. Pharmacol Rev (2008) 2.52
Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors. Circulation (2009) 2.41
Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J (2008) 2.36
Hot flashes and subclinical cardiovascular disease: findings from the Study of Women's Health Across the Nation Heart Study. Circulation (2008) 2.33
Prophylactic oophorectomy in premenopausal women and long-term health. Menopause Int (2008) 2.26
The timing hypothesis and hormone replacement therapy: a paradigm shift in the primary prevention of coronary heart disease in women. Part 1: comparison of therapeutic efficacy. J Am Geriatr Soc (2013) 2.11
Hot flushes, coronary heart disease, and hormone therapy in postmenopausal women. Menopause (2009) 2.07
Pleiotropic actions of estrogen: a mitochondrial matter. Physiol Genomics (2012) 2.07
Timing of hormone therapy, type of menopause, and coronary disease in women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. Menopause (2011) 2.06
Hot flashes and cardiac vagal control: a link to cardiovascular risk? Menopause (2010) 2.02
Estrogen and mechanisms of vascular protection. Arterioscler Thromb Vasc Biol (2009) 2.01
Hot flashes and carotid intima media thickness among midlife women. Menopause (2011) 1.99
Sex differences in autoimmune disease from a pathological perspective. Am J Pathol (2008) 1.94
Associations of endogenous sex hormones with the vasculature in menopausal women: the Study of Women's Health Across the Nation (SWAN). Menopause (2008) 1.94
Increased cardiovascular mortality after early bilateral oophorectomy. Menopause (2009) 1.89
Premature menopause or early menopause and risk of ischemic stroke. Menopause (2012) 1.84
Attitudes of obstetrician-gynecologists toward the evidence from the Women's Health Initiative hormone therapy trials remain generally skeptical. Menopause (2009) 1.80
Hot flashes and cardiac vagal control during women's daily lives. Menopause (2012) 1.78
Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause (2008) 1.74
Vasomotor symptoms and cardiovascular events in postmenopausal women. Menopause (2011) 1.72
Age-specific effects of hormone therapy use on overall mortality and ischemic heart disease mortality among women in the California Teachers Study. Menopause (2011) 1.67
Arterial calcification and bone physiology: role of the bone-vascular axis. Nat Rev Endocrinol (2012) 1.66
Effectiveness of yoga for menopausal symptoms: a systematic review and meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med (2012) 1.66
History of hot flashes and aortic calcification among postmenopausal women. Menopause (2010) 1.63
Age at natural menopause and risk of ischemic stroke: the Framingham heart study. Stroke (2009) 1.57
Menopausal hormone therapy is associated with having high blood pressure in postmenopausal women: observational cohort study. PLoS One (2012) 1.56
Effects of the menopause transition and hormone use on cognitive performance in midlife women. Neurology (2009) 1.53
Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women's Health Initiative Observational Study. Menopause (2014) 1.50
Oophorectomy, menopause, estrogen treatment, and cognitive aging: clinical evidence for a window of opportunity. Brain Res (2010) 1.48
Vasomotor symptoms and coronary artery calcium in postmenopausal women. Menopause (2010) 1.47
Age at menopause, reproductive history, and venous thromboembolism risk among postmenopausal women: the Women's Health Initiative Hormone Therapy clinical trials. Menopause (2014) 1.46
Ischaemic heart disease in women: are there sex differences in pathophysiology and risk factors? Position paper from the working group on coronary pathophysiology and microcirculation of the European Society of Cardiology. Cardiovasc Res (2010) 1.45
Estrogen alone and joint symptoms in the Women's Health Initiative randomized trial. Menopause (2013) 1.42
Further evidence for promoting transdermal estrogens in the management of postmenopausal symptoms. Menopause (2011) 1.40
Changing concepts: Menopausal hormone therapy and breast cancer. J Natl Cancer Inst (2012) 1.39
Gender differences in the cardiovascular effect of sex hormones. Nat Rev Cardiol (2009) 1.39
Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the women's health initiative trials of hormone therapy. Arch Intern Med (2008) 1.34
Bone mineral density in estrogen-deficient young women. J Clin Endocrinol Metab (2009) 1.33
Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. J Natl Cancer Inst (2010) 1.31
Duration of menopausal hot flushes and associated risk factors. Obstet Gynecol (2011) 1.31
Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009. Menopause (2011) 1.31
Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist. Mol Cell Endocrinol (2007) 1.30
Estrogen treatment in multiple sclerosis. J Neurol Sci (2009) 1.29
Estrogen therapy: is time of initiation critical for neuroprotection? Nat Rev Endocrinol (2009) 1.29
Estrogen treatment after ovariectomy protects against fatty liver and may improve pathway-selective insulin resistance. Diabetes (2012) 1.28
Estrogen, hormonal replacement therapy and cardiovascular disease. Curr Opin Nephrol Hypertens (2011) 1.24
Estrogen receptor-beta prevents cardiac fibrosis. Mol Endocrinol (2010) 1.24
Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases. Front Neuroendocrinol (2008) 1.23
The transactivating function 1 of estrogen receptor alpha is dispensable for the vasculoprotective actions of 17beta-estradiol. Proc Natl Acad Sci U S A (2009) 1.23
Hormone therapy and cognitive function. Hum Reprod Update (2009) 1.22
Estrogen receptors and human disease: an update. Arch Toxicol (2012) 1.22
Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings. Genome Med (2009) 1.21
Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev (2012) 1.20
Limitations of observational evidence: implications for evidence-based dietary recommendations. Adv Nutr (2014) 1.19
The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. Int J Clin Pract (2007) 1.17
Rapid recruitment of temporally distinct vascular gene sets by estrogen. Mol Endocrinol (2008) 1.16
Women's health in menopause with a focus on hypertension. Neth Heart J (2009) 1.15
Differential effects of sex steroids in young and aged female mRen2.Lewis rats: a model of estrogen and salt-sensitive hypertension. Gend Med (2008) 1.14
Coronary heart disease in women: a challenge for the 21st century. Clinics (Sao Paulo) (2010) 1.14
Vasomotor symptoms and insulin resistance in the study of women's health across the nation. J Clin Endocrinol Metab (2012) 1.13
Stroke risk in women: the role of menopause and hormone therapy. Lancet Neurol (2012) 1.10
Estrogen, aging and the cardiovascular system. Future Cardiol (2009) 1.09
Are vasomotor symptoms associated with alterations in hemostatic and inflammatory markers? Findings from the Study of Women's Health Across the Nation. Menopause (2011) 1.07
Brain volumes, cognitive impairment, and conjugated equine estrogens. J Gerontol A Biol Sci Med Sci (2009) 1.05
Sex steroidal hormones and respiratory control. Respir Physiol Neurobiol (2008) 1.03
Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events. Am J Cardiol (2008) 1.03
The menstrual cycle: a biological marker of general health in adolescents. Ann N Y Acad Sci (2008) 1.03
Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. Am J Med (2011) 1.02
Influence of sex hormones and phytoestrogens on heart disease in men and women. Womens Health (Lond Engl) (2010) 1.02
Sex hormone modulation of proinflammatory cytokine and C-reactive protein expression in macrophages from older men and postmenopausal women. J Endocrinol (2010) 1.02
An intensive behavioral weight loss intervention and hot flushes in women. Arch Intern Med (2010) 1.00
Total estrogen time and obstructive coronary disease in women: insights from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE). J Womens Health (Larchmt) (2009) 1.00
Vasomotor symptoms and lipid profiles in women transitioning through menopause. Obstet Gynecol (2012) 1.00
Drug and cell type-specific regulation of genes with different classes of estrogen receptor beta-selective agonists. PLoS One (2009) 0.99
Obesity and altered glucose metabolism impact HDL composition in CETP transgenic mice: a role for ovarian hormones. J Lipid Res (2012) 0.99
Gender differences in cardiovascular disease: hormonal and biochemical influences. Reprod Sci (2010) 0.99
Methods and baseline cardiovascular data from the Early versus Late Intervention Trial with Estradiol testing the menopausal hormone timing hypothesis. Menopause (2015) 0.98
Short-term and long-term effects of osteoporosis therapies. Nat Rev Endocrinol (2015) 0.98
Role of aging versus the loss of estrogens in the reduction in vascular function in female rats. Endocrinology (2008) 0.98
Feeling too hot or cold after breast cancer: is it just a nuisance or a potentially important prognostic factor? Int J Hyperthermia (2010) 0.97
Sex and gender differences in myocardial hypertrophy and heart failure. Wien Med Wochenschr (2011) 0.97
Phytoestrogens in postmenopause: the state of the art from a chemical, pharmacological and regulatory perspective. Curr Med Chem (2014) 0.96
Estradiol is a potent protective, restorative, and trophic factor after brain injury. Semin Reprod Med (2009) 0.96
Activation function 2 (AF2) of estrogen receptor-alpha is required for the atheroprotective action of estradiol but not to accelerate endothelial healing. Proc Natl Acad Sci U S A (2011) 0.96
A "window of opportunity:" the reduction of coronary heart disease and total mortality with menopausal therapies is age- and time-dependent. Brain Res (2010) 0.96
Traditional nonsteroidal anti-inflammatory drugs and postmenopausal hormone therapy: a drug-drug interaction? PLoS Med (2007) 0.95
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab (2010) 13.29
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA (2004) 11.69
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61
Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women. JAMA (2003) 10.05
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62
Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study--a large observational study of the determinants of fracture in older men. Contemp Clin Trials (2005) 9.57
A prospective study of sleep duration and coronary heart disease in women. Arch Intern Med (2003) 9.24
Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 9.03
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
Estrogen therapy and coronary-artery calcification. N Engl J Med (2007) 8.70
Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med (2004) 8.63
Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 8.32
Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med (2002) 7.77
National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA (2004) 7.68
A prospective study of self-reported sleep duration and incident diabetes in women. Diabetes Care (2003) 7.40
Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med (2002) 7.32
Implementation of the Women's Health Initiative study design. Ann Epidemiol (2003) 7.30
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12
Frailty: emergence and consequences in women aged 65 and older in the Women's Health Initiative Observational Study. J Am Geriatr Soc (2005) 6.73
Calcium/vitamin D supplementation and cardiovascular events. Circulation (2007) 6.63
Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation (2003) 6.62
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med (2014) 6.51
Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med (2010) 6.48
Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med (2006) 6.22
Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med (2009) 6.16
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) (2002) 6.03
Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med (2004) 5.86
Low-fat dietary pattern and weight change over 7 years: the Women's Health Initiative Dietary Modification Trial. JAMA (2006) 5.75
Coffee consumption and risk for type 2 diabetes mellitus. Ann Intern Med (2004) 5.67
Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med (2010) 5.60
Smoking and mortality--beyond established causes. N Engl J Med (2015) 5.54
Effects of estrogen with and without progestin on urinary incontinence. JAMA (2005) 5.41
Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 5.25
Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet (2009) 5.22
Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 5.13
Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med (2010) 5.05
Physical activity, including walking, and cognitive function in older women. JAMA (2004) 4.90
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87
Effects of estrogen plus progestin on health-related quality of life. N Engl J Med (2003) 4.83
Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med (2009) 4.80
Red meat consumption and mortality: results from 2 prospective cohort studies. Arch Intern Med (2012) 4.72
Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes (2004) 4.67
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63
Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol (2005) 4.55
Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA (2003) 4.54
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA (2008) 4.42
Multivitamins in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 4.40
Glycemic index, glycemic load, and dietary fiber intake and incidence of type 2 diabetes in younger and middle-aged women. Am J Clin Nutr (2004) 4.29
Use of recovery biomarkers to calibrate nutrient consumption self-reports in the Women's Health Initiative. Am J Epidemiol (2008) 4.28
Dietary patterns, meat intake, and the risk of type 2 diabetes in women. Arch Intern Med (2004) 4.27
Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study. Arch Intern Med (2005) 4.24
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.21
Low-carbohydrate-diet score and the risk of coronary heart disease in women. N Engl J Med (2006) 4.16